Table 4 Study of iguratimod in lupus nephritis key secondary outcomes

1

Proportion of participants with renal remission by 24 weeks.

2

Proportion of participants with flare by 52 weeks

3

Number of participants with treatment-related adverse events which are assessed by CTCAE v4.0b by 52 weeks

4

SLE disease activity index (2000) (SLEDAI-2 K) score by 52 weeks

5

British Isles lupus assessment group (BILAG) score by 52 weeks

6

Patient general assessment (PGA)